NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/21/2025
Back to search
Official data from USPTO
HYLORIS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
HYLORIS
ST13
US500000097401213Class
5, 40, 42
Filing
97401213
Registration
7656999
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
01/21/2025
Trademark type
Word
Nice classes
5, 40, 42
Filing date
05/09/2022
Registration date
01/21/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/21/2025
Last transaction
01/21/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
33
Owner location
Liège, BE
Examiner
CORDANI, CAITLIN
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Hyloris Pharmaceuticals SA
Representatives
Clifford D Hyra FRESH IP PLC
Technical classification
Nice Classes
Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Cardiovascular pharmaceuticals; Cardiovascular pharmaceutical preparations; Pharmaceutical preparations and substances for the treatment of cardiovascular and cardiopulmonary diseases and disorders; Pharmaceutical preparations for the treatment of heart rhythm disorders; Medicines for the treatment of cardiovascular and cerebrovascular diseases; none of the aforementioned for the treatment of non-cardiological inflammatory disorders
Class 40
Custom manufacture of cardiovascular pharmaceuticals and medicines for treatment of cardiovascular diseases by pharmaceutical compounders; providing technical information in the field of pharmaceutical manufacturing of cardiovascular pharmaceuticals; biomanufacturing for othersmanufacturing of cardiovascular pharmaceuticals using biological organisms in the manufacturing process
Class 42
Pharmaceutical research and development services in the field of cardiovascular and cardiopulmonary disease and disorders; Development of cardiovascular pharmaceutical preparations and medicines for the treatment of cardiovascular diseases; cardiovascular pharmaceutical products development; Laboratory research services in the field of pharmaceuticals and new productscardiovascular pharmaceutical and biotechnological products in the nature of cardiovascular pharmaceuticals; conducting early evaluations in the field of new cardiovascular pharmaceuticals; testinginspection and research of cardiovascular pharmaceuticals; research and development in the biotechnology fields in relation to cardiovascular and cardiopulmonary diseases and disorders; technical consulting services in the fields of pharmaceutical research and developmentbiotechnology; technical consulting services in the field of scientific laboratory serviceslaboratory testingdiagnostics; all the aforementioned in relation to cardio vascular and cardiopulmonary diseases and disorders
Publications
History of USPTO decisions and trademark events.
44 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/21/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/03/2024
PUBO
PUBLISHED FOR OPPOSITION
12/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/27/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/15/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/18/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/18/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/18/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/09/2024
GNRT
NON-FINAL ACTION E-MAILED
08/09/2024
CNRT
NON-FINAL ACTION WRITTEN
08/09/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/16/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/16/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
07/15/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/09/2024
GNSL
LETTER OF SUSPENSION E-MAILED
05/09/2024
CNSL
SUSPENSION LETTER WRITTEN
05/09/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/18/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/18/2024
ALIE
ASSIGNED TO LIE
04/18/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
11/29/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
09/18/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
09/18/2023
CNSI
SUSPENSION INQUIRY WRITTEN
09/18/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/17/2023
GNSL
LETTER OF SUSPENSION E-MAILED
03/17/2023
CNSL
SUSPENSION LETTER WRITTEN
03/17/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
03/15/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/15/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
03/15/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/15/2023
DOCK
ASSIGNED TO EXAMINER
02/27/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/18/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/18/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/18/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/31/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/31/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/31/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/31/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/31/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/31/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/13/2022
NWAP
NEW APPLICATION ENTERED
05/12/2022
Continuous trademark protection
Get notified about every new filing that threatens HYLORIS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.